Scientific Reports · 2019 · 13 citations · 24 references
MedicineGeriatric MedicinePulmonologyRisk AssessmentSurvival AnalysisComparative Mortality AnalysisComprehensive Geriatric AssessmentPrognostic AssessmentPulmonary EmbolismSurvival OutcomesOutcome PrognosticationPositive Predictive ValuePrognostic CriteriaPrognostic Index DevelopmentPrognostic IndicesPrognostic PredictionPrognostic VariablesPulmonary Embolism Risk Stratification
In young patients with acute pulmonary embolism (PE), the predictive value of currently available prognostic tools has not been evaluated. Our objective was to compare prognostic value of 7 available tools (GPS, PESI, sPESI, Prognostic Algorithm, PREP, shock index and RIETE) in patients aged <50 years. We used the RIETE database, including PE patients from 2001 to 2017. The major outcome was 30-day all-cause mortality. Of 34,651 patients with acute PE, 5,822 (17%) were aged <50 years. Of these, 83 (1.4%) died during the first 30 days. Number of patients deemed low risk with tools was: PREP (95.9%), GPS (89.6%), PESI (87.2%), Shock index (70.9%), sPESI (59.4%), Prognostic algorithm (58%) and RIETE score (48.6%). The tools with a highest sensitivity were: Prognostic Algorithm (91.6%; 95% CI: 85.6-97.5), RIETE score (90.4%; 95%CI: 84.0-96.7) and sPESI (88%; 95% CI: 81-95). The RIETE, Prognostic Algorithm and sPESI scores obtained the highest overall sensitivity estimates for also predicting 7- and 90-day all-cause mortality, 30-day PE-related mortality, 30-day major bleeding and 30-day VTE recurrences. The proportion of low-risk patients who died within the first 30 days was lowest using the Prognostic Algorithm (0.2%), RIETE (0.3%) or sPESI (0.3%) scores. In PE patients less 50 years, 30-day mortality was low. Although sPESI, RIETE and Prognostic Algorithm scores were the most sensitive tools to identify patients at low risk to die, other tools should be evaluated in this population to obtain more efficient results.
24
Antithrombotic Therapy for VTE Disease
Clive Kearon, Elie A. Akl, Anthony J. Comerota et al. · CHEST Journal · 2012 · 6.1K citations · Full text
Antithrombotic Therapy for VTE Disease
Clive Kearon, Elie A. Akl, Joseph Ornelas et al. · CHEST Journal · 2016 · 4.8K citations
Stavros Konstantinides, Guy Meyer, Cecilia Becattini et al. · European Heart Journal · 2019 · 4.8K citations · Full text
Antithrombotic Therapy for Venous Thromboembolic Disease
Clive Kearon, Susan R. Kahn, Giancarlo Agnelli et al. · CHEST Journal · 2008 · 2K citations
Stavros Konstantinides, Guy Meyer, Cecilia Becattini et al. · European Respiratory Journal · 2019 · 1.6K citations · Full text